BACKGROUND: Friedreich's ataxia (FA) is a genetic disorder caused by a severe decrease in FXN (frataxin) protein expression in mitochondria. The clinical manifestation of this disorder is a cerebellar ataxia; however, the common lethal component in FA is cardiomyopathy. METHODS: A conditional Fxn(flox/null)::MCK-Cre knockout (FXN-cKO) mouse model was used to mimic the late-stage severe cardiomyopathy in FA. Nrf2 (nuclear factor erythroid 2-related factor 2) inducers, omaveloxolone and dimethyl fumarate (DMF), were independently tested in this mouse model to determine the effects on cardiac health and lifespan. RESULTS: Omaveloxolone significantly improved cardiac contractile function and markers of heart failure in FA such as Nppb, Aldh1a3, and Gdf15. Despite improvement in cardiac function, omaveloxolone did not prevent premature death in FXN-cKO animals and notably accelerated death in FXN-cKO females. Omaveloxolone decreased oxidative stress and inflammatory marker IL1β (interleukin-1 beta), and stimulated Nqo1 gene expression above control level. DMF restored elevated HO-1 (Hmox) expression and significantly increased Sirt1 expression. Although both omaveloxolone and DMF restored decreased SERCA2 (Atp2a) and MCU (Mcu) expression and ameliorated elevated phosphorylation of CaMKIIδ at Thr(286) site in FA hearts, DMF did not improve cardiac contractile function and survival. Furthermore, neither omaveloxolone or DMF decreased hypertrophy and fibrosis (Masson trichrome staining and Lgals3 expression) or rescued impaired mitochondrial function and integrative stress response in FXN-cKO hearts. CONCLUSIONS: These data demonstrate that omaveloxolone significantly improved contractile function but not survival in FA hearts because cardiac fibrosis and wall stress persisted even with omaveloxolone treatment. More studies are warranted to determine the cause of premature death in omaveloxolone-treated FXN-cKO female mice.
Omaveloxolone, But Not Dimethyl Fumarate, Improves Cardiac Function in Friedreich's Ataxia Mice With Severe Cardiomyopathy.
奥马维洛酮(Omaveloxolone)而非富马酸二甲酯(Dimethyl Fumarate)可改善患有严重心肌病的弗里德赖希共济失调小鼠的心脏功能
阅读:10
作者:Salinas Lili, Figueroa Francisco, Montgomery Claire B, Thai Phung N, Chiamvimonvat Nipavan, Cortopassi Gino, Dedkova Elena N
| 期刊: | Journal of the American Heart Association | 影响因子: | 5.300 |
| 时间: | 2025 | 起止号: | 2025 Jun 17; 14(12):e038505 |
| doi: | 10.1161/JAHA.124.038505 | 研究方向: | 心血管 |
| 疾病类型: | 心肌病 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
